Similar articles

• Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.

  DeJesus E, Wald A, Warren T, Schacker TW, Trottier S, Shahmanesh M, Hill JL, Brennan CA; Valacyclovir International HSV Study Group. DeJesus E, et al. J Infect Dis. 2003 Oct 1;188(7):1009-16. doi: 10.1086/378416. Epub 2003 Sep 10. J Infect Dis. 2003. PMID: 14513421 Clinical Trial.
• Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.

  Warren T, Harris J, Brennan CA. Warren T, et al. Clin Infect Dis. 2004 Nov 1;39 Suppl 5:S258-66. doi: 10.1086/422362. Clin Infect Dis. 2004. PMID: 15494897 Clinical Trial.
• Trial shows HSV-2 suppression can reduce HIV shedding.

  [No authors listed] [No authors listed] IAVI Rep. 2006 Jan-Feb;10(1):20. IAVI Rep. 2006. PMID: 16628770 Clinical Trial. No abstract available.
• Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir.

  Tyring SK, Baker D, Snowden W. Tyring SK, et al. J Infect Dis. 2002 Oct 15;186 Suppl 1:S40-6. doi: 10.1086/342966. J Infect Dis. 2002. PMID: 12353186 Review.
• HSV shedding.

  Sacks SL, Griffiths PD, Corey L, Cohen C, Cunningham A, Dusheiko GM, Self S, Spruance S, Stanberry LR, Wald A, Whitley RJ. Sacks SL, et al. Antiviral Res. 2004 Aug;63 Suppl 1:S19-26. doi: 10.1016/j.antiviral.2004.06.004. Antiviral Res. 2004. PMID: 15450382 Review.